Eiger BioPharmaceuticals price target lowered to $24 from $28 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff lowered his price target for Eiger BioPharmaceuticals to $24 to account for dilution from the recent financing. The analyst expects Phase II readouts for exendin in hypoglycemia and ubenimex in lymphedema in Q3. He reiterates an Overweight rating on the shares
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.